Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2b Trial Evaluating Clinical Outcomes of Inhaled Sargramostim in High-risk Patients With Mild-moderate COVID-19

NCT04707664 is registered in ClinicalTrials.gov with Partner Therapeutics, Inc. as lead sponsor.

NCT NCT04707664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04707664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2b Trial Evaluating Clinical Outcomes of Inhaled Sargramostim in High-risk Patients With Mild-moderate COVID-19
Lead sponsor
Partner Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 27, 2021
Completion date
January 31, 2022
Enrollment
600 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, sars-cov infection